This article is more than 5 years old. Information may no longer be current.

Parion begins phase 1/2a clinical trial to treat dry eye disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Parion announced that it enrolled the first patient in the phase 1/2a clinical trial of P-321 ophthalmic solution for the treatment of dry eye disease.

Parion said it will study the pharmacokinetics and pharmacodynamics of P-321 in the target patient population; results are expected in early 2015.

Parion cited in its announcement that previous studies with preclinical models of dry eye disease have demonstrated that by blocking ENaC, the tear film volume is restored, maintaining its protective and lubricating actions on the ocular surface. P-321 is Parion’s effort to develop an ENaC inhibitor with unique pharmacokinetic and pharmacodynamic characteristics designed for topical ocular administration, metabolic stability and limited systemic exposure, according to the announcement.